Showing 1 - 10 of 260
Policy makers use reference pricing to curb pharmaceutical expenditures by reducing coverage of expensive branded drugs. In a theoretical analysis we show that the net effect of reference pricing is generally ambiguous when accounting for entry by generic producers. Reference pricing shifts...
Persistent link: https://www.econbiz.de/10013285854
. Domestic innovation is measured as citation-weighted domestic patents filed at the European Patent Office (EPO): to account for … to patent at the EPO. Results show that, in the short-run, IPR stimulate innovation. The effect for developing countries …
Persistent link: https://www.econbiz.de/10011509446
This paper develops a theory of patent portfolios in which firms accumulate an enormous amount of related patents in … infringe on other firms ́patent portfolios. We investigate how litigation incentives for the holders of patent portfolios … impact the incentives to introduce new products and draw welfare implications. We also consider a patent portfolio …
Persistent link: https://www.econbiz.de/10010189838
This paper analyzes patent pools and their effects on innovation incentives. It is shown that the pro …-competitive effects of patent pools for complementary patents naturally extend for dynamic innovation incentives. However, this simple … case, the licensing fees reflect the strength of patents. Patent pools of complementary patents can be used to discourage …
Persistent link: https://www.econbiz.de/10010199442
This paper develops a model of patent trolls to understand various litigation strategies employed by nonpracticing …
Persistent link: https://www.econbiz.de/10011344729
Our study puts special attention to the fact that R&D cooperations in the pharmaceutical industry are formed at different stages throughout the drug development process. We study if the timing to engage in R&D cooperations in the pharmaceutical industry has different impacts on the technology...
Persistent link: https://www.econbiz.de/10010229875
In the European Union, medicines are regulated products subject to both single market (e.g., regional exhaustion of property rights) and country specific health care regulations (e.g., medicines pricing). This gives rise to parallel trade (PT), a phenomenon that takes place when a patented...
Persistent link: https://www.econbiz.de/10010477153
We provide a theoretical framework to contribute to the current debate regarding the tendency of pharmaceutical companies to direct their R&D toward marketing products that are "follow-on" drugs of already existing drugs, rather than toward the development of breakthrough drugs. We construct a...
Persistent link: https://www.econbiz.de/10011406575
pricing system was changed in 2011 in order to tie prices more to the benefits of the pharmaceuticals. A multiple linear … regression of 187 pharmaceuticals which were assessed from 2011 to 2017 suggests that, despite the change, the manufacturers …
Persistent link: https://www.econbiz.de/10012119750
Pharmaceutical firms spend increasing amounts in mergers and acquisitions (M&As), which raises the question of whether sufficient investment is left after mergers to further develop firms' internal drug development capability. We evaluate the effects of M&As on firms' post-merger R&D...
Persistent link: https://www.econbiz.de/10012219372